Funder: National Institutes of Health

Due Dates: May 13, 2025 (Earliest Submission) | June 13, 2025 (Full Application) | Letter of Intent: May 14, 2025

Funding Amounts: Up to $250,000 direct costs/year (UG3, max 3 years); up to $400,000 direct costs/year (UH3, max 2 years); up to 5 years total.

Summary: Supports phased discovery and development of novel, safe, non-toxic natural products for cancer interception and prevention; clinical trials are not allowed.

Key Information: UG3/UH3 application must be submitted as a single application; transition to UH3 phase is milestone-dependent.